InnoVet Inc. of West Palm Beach, Fla., added chief executiveofficer to the title of Jesse Houdeshell, who had been presidentand chief operating officer. Scott Cielewich was promoted toexecutive vice president and chief financial officer from CFO.Daniel Ansley, president of the wholly owned subsidiary DRA &Associates, was named vice president, scientific affairs, atInnoVet. And Daniel Walker was named vice president, salesand marketing. He was vice president of operations forFermenta Animal Health Company. InnoVet also named to itsboard Cielewich and Howard Thomas, president of CambridgeVeterinary Sciences.

Lars Ostberg was named senior scientist at Protein Design Labsof Mountain View, Calif. Ostberg was director of monoclonalantibody research at Sandoz and led the development ofhuman anti-viral antibodies that PDL recently acquired fromSandoz Pharma Ltd. and Sandoz Pharmaceuticals Corp.

Cytomed Inc. of Cambridge, Mass., named Tesfaye Biftu seniordirector, medicinal chemistry, and Paul Higgins principalscientist. Biftu was senior research fellow at Merck & Co., andHiggins was research scientist in the department ofimmunology at Repligen Corp.

Creative BioMolecules Inc. of Hopkinton, Mass., appointed to itsboard of directors Martyn Greenacre, chairman of the board,president and CEO of Zynaxis Inc.

Macronex Inc. of Research Triangle Park, N.C., named to itsscientific advisory board Thomas Glenn, president and chiefoperating officer of Phytopharmaceuticals, and Seth Rudnick,chariman and chief executive officer of CytoTherapeutics Inc.

LifeCell Corp. of The Woodlands, Texas, elected as directors fora one-year term: Paul Frison, chairman, president and CEO;Stephen Livesey, executive VP and chief scientific officer;Michael Cahr, venture group manager, Allstate Venture Capital;P. William Curreri, president of Strategem of Alabama Inc. andLifeCell's consulting director of clinical and regulatory affairs;Christopher Kraft, former director, Johnson Space Center;Thomas Ricks, vice chancellor for asset management, TheUniversity of Texas System; and Martin Sutter, managinggeneral partner, The Woodlands Venture Fund, L.P.

(c) 1997 American Health Consultants. All rights reserved.

No Comments